NYSE:LLY实时 871.86-1.11-0.13%2025-02-13 16:00:02 今开:877.07 昨收:872.97 今日区间:867.80-883.50 52周区间:561.65-972.53 成交量:247.13万 成交额:216132.02万 市值:8273.95亿 市盈率:95.11 贝塔系数: 每股收益: 盘前874.574.210.48%成交量0.1万2025-02-14 04:51...
美通社为各个企业或机构提供最新NYSE:LLY新闻稿撰写和NYSE:LLY新闻稿发布服务,保证各个企业或机构的NYSE:LLY新闻稿及时上线,并被搜索引擎抓取、收录和曝光,为企业或机构提供有力的品牌宣传,从而有效提升企业或机构的知名度。
礼来(LLY) 787.22 +13.93 (+ 1.80%) 收盘, 2025-01-08 17:05:08 (美东时间) 数据延迟15分钟 +加自选 概览 图表 分时 日K 周K 月K 分钟 昨收:773.29 振幅:2.83% 成交量:340.30万 今开:773.83 换手率:0.38% 成交额:26.79亿 最高:792.56 ...
作者: $礼来(LLY)$礼来公司(NYSE:LLY)今天上午公布了第二季度业绩,超出预期,并上调了2023年的指引。具体来说,对于2023年,管理层目前预测收入在334亿至339亿美元之间(之前的预测范围为312亿至317亿美元),每股收益为9.70至9.90美元。 管理层还表示,donanemab(治疗阿尔茨海默病)和Terzepatide(治疗肥胖症)将在今年...
$礼来(LLY)$$诺和诺德(NVO)$#减肥药#礼来制药(NYSE: LLY)公布了一项具有里程碑意义的临床试验结果。在这项名为SURMOUNT-5的第3b期开放标签随机临床试验中,礼来的Zepbound(tirzepatide)与诺和诺德的Wegovy(semaglutide)展开了首次直接对比,结果展现出令人瞩目的治疗优势。
Eli Lilly (LLY) is falling today due to reports of progress from competitors. The pharmaceutical producer has struggled recently as its share of the obesity treatment pill market has been threatened. An obesity treatment pill from Viking Therapeutics (VK
Eli Lilly’s (NYSE:LLY) Zepbound Shortage Over, Says FDA Steve AndersonDec 20, 2024, 01:36 AM A+ A- Story Highlights Eli Lilly loses a major problem in compounding pharmacies, and its Alzheimer’s drug is approved in China. According to the Food and Drug Administration (FDA), something...
The rise of blockbuster weight-loss drugs like Ozempic is leading to a trend of Americans buying smaller-sized, more risqué clothing designs.
Morgan Stanley has chosen Eli Lilly (LLY) as its top biopharma pick for 2025 and rated another nine names in the space as overweight. Read more here.
NYSE:LLY NYSE:LM NYSE:LMT NYSE:LNC NYSE:LNT NYSE:LOW NYSE:LPG NYSE:LPX NYSE:LQD NYSE:LSI NYSE:LTC NYSE:LTS NYSE:LU NYSE:LUMN NYSE:LUV NYSE:LVS NYSE:LXP NYSE:LYB NYSE:M NYSE:MA NYSE:MAA NYSE:MAC NYSE:MAIN NYSE:MAS NYSE:MAV NYSE:MC NYSE:...